Araştırma Makalesi

Thrombophilic gene variants in patients with coronary artery disease and myocardial infarction

Cilt: 45 Sayı: 4 31 Aralık 2023
PDF İndir
EN

Thrombophilic gene variants in patients with coronary artery disease and myocardial infarction

Abstract

Background and aim: Coronary artery disease (CAD) and myocardial infarction (MI) are cardiovascular diseases that occur due to atherosclerosis (plaque formation) or atherosclerotic obstruction of the coronary arteries. Their genetic basis has been under investigation for a long time, and common variant studies link different genetic loci with these diseases. In this study, we investigated the possible association of coronary artery disease and myocardial infarction with thrombophilic gene variants, including MTHFR C677T and A1298C, Beta fibrinogen -455G/A, Factor XIIIV34L and PAI-1 4G/5G single nucleotide polymorphisms (SNPs). Methods: A total of 128 people (64 patients and 64 controls) were included in the study. Genomic DNA was isolated using the EZ1 blood mini kit. The DNA was amplified and PCR was performed using the PyroMark PCR Kit (Qiagen, Germany). Pyrosequencing reaction was completed by processing with PyroMark Q24 instrument. Results: We found that the PAI-1 4G/5G polymorphism and the 4G allele were significantly associated with coronary artery disease and myocardial infarction (P= 0.01). Although mutant variants were higher in patients, no statistically significant difference was observed between the patient and control groups in terms of FXIII, Beta-fibrinogen and MTHFR variants. Conclusions: It is clear that the PAI-1 4G allele and the 4G/4G genotype have a significant contribution to the development of coronary artery disease and ultimately myocardial infarction. Prophylactic treatment should be considered in patients with this variant.

Keywords

Kaynakça

  1. 1. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812-23.
  2. 2. Buntsma N, van der Pol E, Nieuwland R, Gąsecka A. Extracellular Vesicles in Coronary Artery Disease Adv Exp Med Biol. 2023;1418:81-103.
  3. 3. Lu L, Liu M, Sun R, Zheng Y, Zhang P. Myocardial Infarction: Symptoms and Treatments. Cell Biochem Biophys. 2015 Jul;72(3):865-7.
  4. 4. Truesdell AG, Alasnag MA, Kaul P, Rab ST, Riley RF, Young MN, et al. Intravascular Imaging During Percutaneous Coronary Intervention: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023;81(6):590-605.
  5. 5. Park HS, Sung JH, Ryu CS, Lee JY, Ko EJ, Kim IJ, The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population. J Pers Med. 2020 Nov 28;10(4):257.
  6. 6. Abd El-Aziz TA, Rezk NA. Relation of PAI-1 and TPA genes polymorphisms to acute myocardial infarction and its outcomes in Egyptian patients. Cell Biochem Biophys. 2015;71(1):227-34.
  7. 7. Mlynarska A, Waszyrowski T, Kasprzak JD. Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI-1 gene. J Thromb Haemost. 2006;4(6):1361-6.
  8. 8. Li L, Yu H, Zhang H, Wang J, Hu W. Association between MTHFR C677T polymorphism and risk of coronary artery disease in the Chinese population: meta-analysis. Herz. 2022;47(6):553-563.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Multimorbidite

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

31 Aralık 2023

Gönderilme Tarihi

9 Ekim 2023

Kabul Tarihi

25 Aralık 2023

Yayımlandığı Sayı

Yıl 2023 Cilt: 45 Sayı: 4

Kaynak Göster

AMA
1.Yıldırım ME. Thrombophilic gene variants in patients with coronary artery disease and myocardial infarction. CMJ. 2023;45(4):62-68. doi:10.7197/cmj.1373358